WHO Pharmaceuticals Newsletter 2002, No. 03
(2002; 22 pages) Voir le document au format PDF
Table des matières
Fermer ce répertoireREGULATORY MATTERS
Afficher le documentARISTOLOCHIC ACID - Warnings on more products containing Aristolochic acid
Afficher le documentARTHRIN, OSPORO, POENA AND OTHERS - Presence of undeclared prescription drugs poses health threat
Afficher le documentASPIRIN - Restrictions on use in children extended to teenagers
Afficher le documentBACLOFEN - Life threatening sequelae and/or death with abrupt withdrawal of intrathecal injections
Afficher le documentBEJAI BOWYANTAN - Risk of toxicity in children due to presence of Borneol
Afficher le documentCELECOXIB - CLASS findings added to product label
Afficher le documentEPOETIN-ALFA - Important safety update
Afficher le documentGLITAZONES - strengthens labelling for cardiovascular risks
Afficher le documentHORMONE REPLACEMENT THERAPY (HRT) - Product information updated
Afficher le documentIRINOTECAN - Labelling updated
Afficher le documentKAVA-KAVA - More withdrawals due to hepatotoxic risks
Afficher le documentMELOXICAM - Additional information in package insert
Afficher le documentMISOPROSTOL - Major labelling changes
Afficher le documentNIMESULIDE - Temporary suspension pending further evaluation
Afficher le documentOLANZAPINE - Risk of hyperglycaemia
Afficher le documentPOOLED PLASMA (HUMAN) SOLVENT DETERGENT TREATED - Boxed warning to indicate new contraindication
Afficher le documentPROPOFOL - Contraindication section modified
Afficher le documentROFECOXIB - Reports of gastrointestinal/cardio vascular toxicity; labelling updated
Afficher le documentSIROLIMUS - Correction to drug safety information
Afficher le documentSLIM 10 - Withdrawn due to presence of adulterants
Afficher le documentTAMOXIFEN - Boxed warning added to product label
Afficher le documentTETRABAMATE - Withdrawal due to reports of hepatotoxicity
Afficher le documentVALPROATE - Labelling strengthened
Afficher le documentZONISAMIDE - Prescribing information updated
Ouvrir ce répertoire et afficher son contenuSAFETY OF MEDICINES
Ouvrir ce répertoire et afficher son contenuDRUGS OF CURRENT INTEREST
Ouvrir ce répertoire et afficher son contenuFEATURE
Afficher le documentEVENTS & ANNOUNCEMENTS
 

SLIM 10 - Withdrawn due to presence of adulterants

Singapore. The Singapore health authority has ordered the withdrawal of Slim 10, a herbal product of Chinese origin, popular as a slimming pill. This measure follows more than 20 reports of hyperthyroidism and 2 reports of fulminant hepatic failure in consumers using the product in Singapore. Slim 10 was originally declared to contain only 5 herbal ingredients, namely herba gynostemmae pentaphylli, folium gemmae camelliae sinensi, succus aloes folli siccatus, semen raphani and fructus crataegi. However, the Singapore Pharmacovigilance Centre has detected the presence of adulterants fenfluramine and thyroid gland components in Slim 10. The centre is in the process of investigating the causal relationship of Slim 10 to liver toxicities.

Reference:

Communication from Head (Pharmacovigilance), Centre for Pharmaceutical Administration, Health Sciences Authority, Singapore, 19 Jul 2002.

vers la section précédente vers la section suivante
 

Dernière mise à jour: le 3 mai 2013